GMRE — Stock Film
STOCK FILMSCENE 1/11GMRE · $35.74
Stock Expert AI presents
GMRE
Global Medical REIT Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Global Medical REIT Inc. A quick introduction.

On the stock market since 2016, it operates in the world of real estate. It has 26 employees. Now — the numbers.

on the stock market since 2016
26 employees
$478.1M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.1.

The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.

THE SALES TREND
Sales are growing — but slowly for a company this size.

Average growth of 6% a year over the last 4 years. Red columns mark years that ended in a loss.

$115.8M
2021
$137.2M
2022
$140.9M
2023
$138.4M
2024
$148.2M
2025
In the vault right now:
$0
DEBT: $0
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

What executives did with their own stock over the last 12 months:
30 buy3 sell

Executives buying with their own money is usually read as confidence in the company’s future.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Few are betting against it10/10
WEAK SPOTS
The stock has lost its spark0/10
Thin profit on each sale3/10
Growth has stalled4/10
WORTH WATCHING

Profit per Sale: The profit kept from each sale is thin.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 61% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/3
The product is selling

Sales run at $148.2M a year. A small number, but proof the product has real buyers.

2
THE BRIGHT SIDE · 2/3
Executives are buying their own stock

Over the last 12 months, company executives reported 30 buys and 3 sells. Management buying with its own money is usually read as a good sign.

3
THE BRIGHT SIDE · 3/3
Pays a steady dividend

It pays out $3.30 per share each year — regular cash for whoever holds the stock.

1
THE RISKS · 1/3
Running at a loss

A loss of $12.1M against $148.2M in annual sales.

2
THE RISKS · 2/3
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

3
THE RISKS · 3/3
The price sits above analysts’ target

The stock trades 41% above the average analyst price target.

FINALE · THE GRADE
C
0 / 100 · MoonshotScore

On our five-subject report card, GMRE sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.

The takeaway: GMRE is a high-risk stock — not yet profitable, and its future rides on its product catching on.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 22, 2026 · stockexpertai.com · Stock Film